BSE filing, NSE: GODAVARI. Summary written from the filing by ALFA Finder's alert engine.
Godavari Drugs Ltd: key numbers
- Share price
- ₹125.60
- Market cap
- ₹127.2 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 30.6×Sector 45.9×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Other Announcement
Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.
Godavari Drugs Debt & Borrowing: ₹34 Cr
Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.
- Value
- ₹34.00 Cr
Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Board Meeting Outcome
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Godavari Drugs Capital Structure Change
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
- Value
- ₹5.25 Cr
Godavari Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 10.0% YoY
Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +10.0% YoY
Other annual general meeting announcements
All →Carysil Annual General Meeting
Carysil's postal ballot passed a special resolution appointing Prayasvin B. Patel as Independent Director. Voting results and scrutinizer's report were declared November 2, 2026.
Goodluck India Annual General Meeting
Goodluck India seeks postal ballot approval for object clause changes, registered office shift to Uttarakhand and cost auditor fee ratification. Voting closes December 2, 2026.
Nukleus Office Solutions Annual General Meeting
Nukleus Office Solutions sent a postal ballot notice seeking approval to alter its object clause and double authorised capital. E-voting closes 2 December 2026.
Bharat Global Developers Annual General Meeting
Bharat Global Developers filed its AGM scrutinizer report dated 28 September 2026. All three resolutions, including adoption of audited financials, passed.
Expleo Solutions Annual General Meeting
Expleo Solutions' postal ballot on loan limits for related parties by wholly owned subsidiaries failed to get the requisite majority. The scrutinizer's report confirmed the ordinary resolution was not passed.
P E Analytics Annual General Meeting
P. E. Analytics shareholders approved re-appointment of Singhi Chugh & Kumar as Statutory Auditors for five years at the 2 November 2026 EGM. The meeting was held via VC/OAVM with e-voting.
- Execution
- Five (5) consecutive years